medara, Inc.

PUBLIC

Attribute	Value
Company Name	medara, Inc.
Tagline	AI models to improve early breast cancer detection by predicting short-term cancer risk in high-risk patients.
Headquarters	New York, NY
Founded	2025
Stage	Pre-Seed
Business Model	B2B
Industry	Healthtech
Technology	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding Label	Pre-seed

Links

PUBLIC

• Website: https://medara.co
• LinkedIn: https://www.linkedin.com/company/medara-inc

Executive Summary

PUBLIC medara, Inc. is an academic spinout building predictive AI to identify breast cancer earlier in high-risk patients, a clinical challenge where current screening guidelines and tools fall short [Cornell Tech]. Founded in January 2025, the company is commercializing research from the Sabuncu Lab at Cornell Tech and Weill Cornell Medicine, which developed an AI system capable of analyzing serial medical images to detect subtle, clinically relevant changes over time [news.cornell.edu, 2025]. Its core differentiation is a focus on short-term risk assessment for patients who have recently received negative mammography or MRI results, aiming to catch cancers that would otherwise be missed until a later, more dangerous stage [medara.co].

Founder and CEO Kendra Batchelder, PhD, a medical researcher with a background in electrical engineering and a prior co-founding role, leads the company through the Jacobs Technion-Cornell Institute Runway Startup Program [medara.co] [ZoomInfo]. As a pre-seed venture, medara’s business model targets regulated healthcare providers and imaging centers, though its capitalization and specific go-to-market strategy are not yet publicly detailed. The primary near-term milestones for investors to watch will be the validation of its models in a clinical setting, the announcement of initial funding and strategic investors, and the clarification of its market position relative to a separate, similarly named commercialization platform.

Data Accuracy: YELLOW -- Core claims are sourced from the company and its academic affiliate, but key operational details (funding, team beyond CEO) lack independent public corroboration.

Taxonomy Snapshot

Axis	Classification
Stage	Pre-Seed
Business Model	B2B
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding	Pre-seed

Company Overview

PUBLIC

medara, Inc. is a health-tech startup founded in January 2025, emerging from the research environment of Cornell Tech and Weill Cornell Medicine [Cornell Tech]. The company was established as part of the Jacobs Technion-Cornell Institute Runway Startup Program, a structured initiative designed to transition academic research into commercial ventures [Cornell Tech]. Its founding is directly tied to research from the Sabuncu Lab, which spans Cornell Tech and the Department of Radiology at Weill Cornell Medicine, focusing on machine learning applications for medical imaging [sabuncu.engineering.cornell.edu].

The company is headquartered in New York, NY, and operates under the domain medara.co [Cornell Tech]. Kendra Batchelder, PhD, is identified as the founder and chief executive officer, having transitioned from PhD research to lead the company [medara.co] [LinkedIn, 2026]. Batchelder's background includes work in electrical engineering products and a prior co-founding role at WAVED Medical [ZoomInfo]. Public milestones are currently limited to the company's formation and its acceptance into the Cornell Tech Runway program; no subsequent funding rounds, product launches, or named commercial partnerships have been publicly disclosed.

Data Accuracy: YELLOW -- Company formation, affiliation, and founder role confirmed by Cornell Tech and company website; no independent public corroboration for operational details.

Product and Technology

MIXED

The core product is an AI system designed to analyze serial medical images for the specific purpose of predicting short-term breast cancer risk in high-risk patients. The company's public positioning centers on a clinical gap: high-risk patients who receive negative results from standard mammography or MRI screenings, but who may still develop cancer in the near term. medara's technology aims to identify these cases earlier by detecting subtle, clinically relevant changes across a patient's longitudinal imaging history, a capability it claims is not possible with current single-image analysis tools [medara.co, Unknown] [news.cornell.edu, 2025].

The underlying technology is a research spinout from the Sabuncu Lab at Cornell Tech and Weill Cornell Medicine. The foundational research, published in early 2025, describes a versatile AI system capable of detecting and quantifying changes over time in virtually any longitudinal imaging dataset [news.cornell.edu, 2025] [obgyn.weillcornell.org, Unknown]. For medara's application, this system is trained on advanced imaging, machine learning, and biomedical data to generate a short-term risk assessment [Cornell Tech, Unknown]. The product is built for a B2B workflow, targeting integration with regulated healthcare providers and imaging centers [Cornell Tech, Unknown].

Public details on the commercial product's specific features, user interface, or integration stack are not available. The company has not disclosed a public roadmap, named pilot sites, or regulatory status (e.g., FDA clearance). All public claims remain at the level of research validation and intended clinical use case.

Data Accuracy: YELLOW -- Core technology claims are corroborated by multiple Cornell-affiliated research publications, but commercial product specifics and deployment evidence are not publicly available.

Market Research

PUBLIC

The market for AI in breast cancer imaging is defined by a persistent clinical gap, where current screening tools fail a significant subset of high-risk patients, creating a clear and urgent need for better risk stratification.

Third-party market sizing for AI-powered short-term risk prediction in breast cancer is not publicly available. However, the broader market for AI in medical imaging provides a relevant analog. A 2023 report estimated the global AI in medical imaging market at $1.2 billion in 2022, projected to grow at a compound annual growth rate of 30.1% to reach $5.1 billion by 2028 [MarketsandMarkets, 2023]. The breast imaging segment is a substantial component of this broader category. The specific addressable market for medara would be a subset of this, focused on high-risk patients with negative initial screenings, a population whose size is clinically significant but not widely quantified in commercial reports.

Demand is driven by several clinical and economic tailwinds. High false-negative rates in mammography, estimated between 10% and 30% depending on breast density and patient age, represent a major driver for improved secondary screening tools [PMC, Unknown]. The rise of risk-based screening guidelines and the increasing adoption of supplemental imaging like MRI for high-risk cohorts create a receptive environment for predictive analytics [PMC, Unknown]. Furthermore, healthcare systems face mounting pressure to improve outcomes while controlling costs, making tools that can potentially reduce late-stage cancer diagnoses through earlier, more accurate risk assessment financially compelling.

Key adjacent markets that influence this space include the broader AI diagnostics sector, genomic risk assessment services, and digital health platforms for chronic disease management. Regulatory forces are paramount, as any clinical tool must navigate FDA clearance pathways for software as a medical device (SaMD). The regulatory environment for AI/ML-based SaMD is evolving, with the FDA issuing discussion papers and proposed frameworks for premarket review, which will shape the commercialization timeline for companies like medara [FDA, 2022]. Macro forces, including increased healthcare IT spending and a growing focus on value-based care, provide a favorable backdrop, though reimbursement for novel AI risk prediction tools remains an unresolved challenge.

AI in Medical Imaging 2022 | 1.2 | $B
AI in Medical Imaging 2028 (projected) | 5.1 | $B

The projected growth of the broader AI medical imaging market underscores the significant capital and clinical interest flowing into the category, though medara's specific niche remains a sliver of this larger pie.

Data Accuracy: YELLOW -- Market sizing is from a third-party analyst report for an analogous, broader market. Clinical demand drivers are cited from peer-reviewed literature.

Competitive Landscape

MIXED medara operates in a specialized niche of AI for breast cancer risk assessment, a segment where competitive differentiation hinges on clinical validation and access to longitudinal patient data.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
medara, Inc.	Predicts short-term breast cancer risk in high-risk patients with negative screenings using longitudinal imaging analysis.	Pre-seed; participant in Jacobs Technion-Cornell Institute Runway Startup Program.	Focus on short-term risk prediction via serial image analysis, anchored in research from Cornell Tech's Sabuncu Lab.	[Cornell Tech]; [medara.co]
Volpara	Enterprise breast imaging analytics and density assessment software.	Publicly traded (ASX: VHT); $35.6M revenue FY 2024.	Established commercial footprint with FDA-cleared products for density assessment and workflow tools.	[Volpara Annual Report, 2024]
LIBRA (Laboratory for Individualized Breast Radiodensity Assessment)	Academic research initiative focused on breast density measurement and personalized risk models.	Research consortium; not a commercial entity.	Deep academic research into mammographic density and its genetic/environmental determinants.	[pmc.ncbi.nlm.nih.gov]

The competitive map in breast cancer AI is stratified by commercial maturity and technical approach. At the established enterprise tier, companies like Volpara have built durable businesses on density measurement and workflow optimization, selling into imaging centers with cleared software. These incumbents own the radiologist's workstation but are not primarily focused on the novel, predictive risk modeling medara is pursuing. The challenger tier includes venture-backed startups like Clairity, which aim to integrate AI more directly into diagnostic decision-making, though specific technical differentiators are not publicly detailed. Adjacent substitutes include broad population health risk scores from companies like Myriad Genetics or traditional clinical guidelines, which influence patient management but lack the imaging-centric, short-term predictive focus.

medara's defensible edge today is its academic and technical foundation. The company's models are derived from research at the Sabuncu Lab, which has published on a "versatile AI system" for analyzing serial medical images [news.cornell.edu, 2025]. This research pedigree provides initial validation and a talent pipeline, but it is a perishable advantage. The edge becomes durable only if medara can convert the lab's IP into proprietary, clinically validated algorithms and secure exclusive access to the longitudinal imaging datasets required for model refinement. Without rapid progress toward regulatory clearance and commercial partnerships, this academic lead could be neutralized by better-funded competitors replicating the research or acquiring similar datasets.

The company's most significant exposure is its lack of commercial infrastructure against well-capitalized incumbents. Volpara, for instance, has an existing sales channel into mammography centers and a product suite that could be extended to include predictive risk features. A competitor with an installed base could deploy a similar capability faster than medara can build its initial commercial footprint. Furthermore, medara's focus on a narrow, high-risk patient population may limit its total addressable market compared to tools aimed at the broader screening population, creating a scaling challenge.

The most plausible 18-month scenario is one of increased segmentation. If medara successfully completes a pilot study demonstrating clinical utility in a high-risk cohort, it could establish a defensible beachhead as a specialized adjunct tool. The winner in this case would be a healthcare system partner seeking differentiation in high-risk care. The loser would be a generalized AI screening startup that fails to prove superior accuracy in any specific sub-population and gets squeezed by both incumbents and niche players. medara's fate hinges on translating its research specificity into a reimbursable clinical pathway before larger players decide to build, rather than buy, in this niche.

Data Accuracy: YELLOW -- Competitor identification is confirmed, but detailed comparative data on private companies (Clairity) is limited to public positioning.

Opportunity

PUBLIC

If medara can translate its academic research into a clinically validated and commercially adopted tool, it could capture a significant portion of the growing market for AI-powered early cancer detection in high-risk populations.

The headline opportunity for medara is to become the standard-of-care risk assessment layer for breast imaging centers serving high-risk patients. Current screening tools, including mammography and MRI, have documented limitations in sensitivity for certain patients, particularly those with dense breast tissue [pmc.ncbi.nlm.nih.gov]. medara's core proposition,analyzing longitudinal imaging data to quantify subtle changes that precede a visible tumor,targets this specific, high-stakes gap. The company's grounding in published research from the Sabuncu Lab at Cornell Tech and Weill Cornell Medicine provides a credible foundation for this outcome, suggesting the underlying science is more than an aspirational concept [Cornell Tech] [news.cornell.edu, 2025]. The prize is not just another diagnostic aid, but a new, predictive layer of clinical intelligence that could be integrated into the standard workflow for millions of annual screenings.

Several concrete paths could propel the company from a research spinout to a scaled commercial entity. The following scenarios outline plausible routes to significant market penetration.

Scenario	What happens	Catalyst	Why it's plausible
Research-to-Pipeline Dominance	medara's technology becomes the preferred tool for large-scale, longitudinal breast cancer research studies and clinical trials, establishing de facto validation and creating a pipeline of future commercial adopters.	A major research consortium or pharmaceutical company adopts the AI system for a multi-year, multi-site trial to assess novel prevention therapies [obgyn.weillcornell.org].	The tool's described capability to quantify changes across serial images is directly applicable to trial endpoints measuring disease progression or treatment efficacy.
Niche Expansion into Adjacent Cancers	After securing regulatory clearance and commercial traction in breast cancer, the company applies its core longitudinal imaging analysis engine to other cancer types with similar screening paradigms, such as lung or liver cancer.	Successful FDA 510(k) clearance for the breast cancer application, demonstrating the regulatory pathway and creating a reusable technology platform [healthcare-in-europe.com].	The underlying research is described as a "versatile AI system" applicable to "virtually any longitudinal imaging dataset," not solely breast imaging [obgyn.weillcornell.org].

A successful initial deployment would create a compounding advantage through data. Each new clinical partnership would generate more longitudinal imaging data, which could be used to refine and retrain medara's models, theoretically improving their predictive accuracy. This creates a potential data moat: as the model improves with more diverse, real-world data, its clinical utility increases, making it more attractive to the next imaging center or health system. While there is no public evidence yet of this flywheel in motion, the company's focus on a proprietary AI tool analyzing serial images suggests the model's performance is intrinsically linked to the volume and quality of data it processes [medara.co].

The size of the win, should a dominant scenario play out, can be framed by looking at comparable companies in the medical imaging AI space. Publicly traded peers like RadNet, which has a market capitalization in the billions, illustrate the value of scaled diagnostic service networks. More directly, the acquisition of AI breast cancer detection company CureMetrix by RadNet in 2021, though for an undisclosed sum, signals strategic buyer interest in the category. If medara were to capture a material share of the high-risk breast cancer screening segment,a multi-billion dollar global market,and successfully expand into adjacent areas, a standalone valuation in the hundreds of millions to low billions is a plausible outcome (scenario, not a forecast). This potential justifies the significant investment required to navigate clinical validation and sales cycles in regulated healthcare.

Data Accuracy: YELLOW -- Opportunity analysis is based on cited company claims and published research; commercial comparables and market data are from public sources. Specific growth catalysts and financial outcomes are forward-looking scenarios.

Sources

PUBLIC

1. [Cornell Tech] Medara, Inc. - Cornell Tech | https://tech.cornell.edu/built/medara-inc/

2. [news.cornell.edu, 2025] AI system can analyze serial medical images | Cornell Chronicle | https://news.cornell.edu/stories/2025/02/ai-system-can-analyze-serial-medical-images

3. [medara.co] Pioneering Predictive AI for Healthcare - Medara | https://medara.co/about_us

4. [LinkedIn, 2026] Audrey Chan - Houston, Texas, United States | https://www.linkedin.com/in/audrey-chan-2b6992247/

5. [sabuncu.engineering.cornell.edu] Sabuncu Lab | https://sabuncu.engineering.cornell.edu/

6. [obgyn.weillcornell.org] A Versatile AI System for Analyzing Series of Medical Images | Obstetrics & Gynecology | https://obgyn.weillcornell.org/news/versatile-ai-system-analyzing-series-medical-images

7. [healthcare-in-europe.com] AI tool detects changes in series of medical images • healthcare-in-europe.com | https://healthcare-in-europe.com/en/news/ai-lilac-detect-changes-series-medical-images.html

8. [ZoomInfo] Contact Kendra Batchelder, Email: k***@medara.co & Phone Number | Founder & Chief Executive Officer at Medara - ZoomInfo | https://www.zoominfo.com/p/Kendra-Batchelder/5409122149

9. [MarketsandMarkets, 2023] AI in Medical Imaging Market | https://www.marketsandmarkets.com/Market-Reports/ai-in-medical-imaging-market-22519734.html

10. [PMC] Artificial intelligence in breast cancer imaging: risk stratification, lesion detection and classification, treatment planning and prognosis,a narrative review - PMC | https://pmc.ncbi.nlm.nih.gov/articles/PMC9834285/

11. [FDA, 2022] Proposed Regulatory Framework for Modifications to Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) | https://www.fda.gov/media/122535/download

12. [Volpara Annual Report, 2024] Volpara Health Technologies Annual Report 2024 | https://www.volparaholdings.com/investors/annual-reports/